Targeting p53 Y220C: Dr Dale Shepard Discusses Rezatapopt Findings

The TP53 gene has long been the "white whale" of oncology. Mutated in roughly half of all human cancers, it was considered undruggable for decades. However, data from the PYNNACLE phase 1 trial (NCT04585750), recently published in The New England Journal of Medicine, suggests that a precision medicine approach may finally be turning the tide.